{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T20:42:31Z","timestamp":1750452151084,"version":"3.37.3"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81403145"],"award-info":[{"award-number":["81403145"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"publisher","award":["20JR10RA602","23ZDFA013-4","21JR7RA439"],"award-info":[{"award-number":["20JR10RA602","23ZDFA013-4","21JR7RA439"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.cbi.2024.111248","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T06:23:22Z","timestamp":1727245402000},"page":"111248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Structure optimization, synthesis and bioactivity evaluation of novel BCR-ABL tyrosine kinase inhibitor targeting T315I mutation"],"prefix":"10.1016","volume":"403","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2301-4555","authenticated-orcid":false,"given":"Shuo","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6540-0584","authenticated-orcid":false,"given":"Rui","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijing","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaihuai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhesheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiazhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7510-4005","authenticated-orcid":false,"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2024.111248_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda B","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cbi.2024.111248_bib2","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","article-title":"Chronic myeloid leukaemia","volume":"398","author":"Cortes J","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cbi.2024.111248_bib3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.canep.2013.01.002","article-title":"Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries","volume":"37","author":"Mendizabal Am","year":"2013","journal-title":"Cancer Epidemiology"},{"key":"10.1016\/j.cbi.2024.111248_bib4","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors","volume":"127","author":"Jain P","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cbi.2024.111248_bib5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.biopha.2015.06.004","article-title":"Preclinical model for identification of therapeutic targets for CML offers clues for handling imatinib resistance","volume":"73","author":"Molli","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cbi.2024.111248_bib6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1084\/jem.181.1.307","article-title":"Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the bcr-abl","volume":"181","author":"Sawyers Cl","year":"1995","journal-title":"Oncogene Journal of experimental medicine"},{"key":"10.1016\/j.cbi.2024.111248_bib7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1358\/dot.2022.58.10.3441853","article-title":"Asciminib in chronic myeloid leukemia","volume":"58","author":"Assanto","year":"2022","journal-title":"Drugs Today"},{"key":"10.1016\/j.cbi.2024.111248_bib8","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare T","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cbi.2024.111248_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah Np","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cbi.2024.111248_bib10","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler T","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.cbi.2024.111248_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","article-title":"Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias","volume":"4","author":"Gambacorti-Passerini Cb","year":"2003","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cbi.2024.111248_bib12","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun Tp","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cbi.2024.111248_bib13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.canlet.2019.11.040","article-title":"Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia","volume":"472","author":"Gupta P","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cbi.2024.111248_bib14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cbi.2024.111248_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113064","article-title":"The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine","volume":"150","author":"Li","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cbi.2024.111248_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109677","article-title":"Acetylshikonin induces apoptosis of human leukemia cell line K562 by inducing S phase cell cycle arrest, modulating ROS accumulation, depleting Bcr-Abl and blocking NF-\u03baB signaling","volume":"122","author":"Hao","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cbi.2024.111248_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112330","article-title":"JKST6, a novel multikinase modulator of the BCR-ABL1\/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia","volume":"144","author":"Aranda-Tav\u00edo","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cbi.2024.111248_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1036437","article-title":"A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia","volume":"12","author":"Qian","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cbi.2024.111248_bib19","article-title":"The discovery of novel BCR-ABL tyrosine kinase inhibitors using a pharmacophore modeling and virtual screening approach","volume":"9","author":"Huang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.cbi.2024.111248_bib20","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3390\/ph6060700","article-title":"Virtual lead identification of farnesyltransferase inhibitors based on ligand and structure-based pharmacophore techniques","volume":"6","author":"Al-Balas Qa","year":"2013","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.cbi.2024.111248_bib21","article-title":"Virtual screening and bioactivity evaluation of novel androgen receptor antagonists from anti-PCa traditional Chinese medicine prescriptions","volume":"8","author":"Han W","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.cbi.2024.111248_bib22","first-page":"625","article-title":"Expanded phase 1 study of ABL001, a potent, allosteric inhibitor of BCR-ABL, reveals significant and durable responses in patients with CML-chronic phase with failure of prior TKI therapy","volume":"128","author":"Iyer","year":"2016","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.cbi.2024.111248_bib23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejmech.2015.09.034","article-title":"Expanding the structural diversity of Bcr-Abl inhibitors: dibenzoylpiperazin incorporated with 1H-indazol-3-amine","volume":"2","author":"Shan Y","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cbi.2024.111248_bib24","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1016\/j.bmcl.2015.08.013","article-title":"Expanding the structural diversity of Bcr-Abl inhibitors: hybrid molecules based on GNF-2 and Imatinib","volume":"25","author":"Pan X","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.cbi.2024.111248_bib25","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1021\/jm100555f","article-title":"Expanding the diversity of allosteric bcr-abl inhibitors","volume":"53","author":"Deng X","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2024.111248_bib26","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1158\/1078-0432.CCR-13-3317","article-title":"Dual inhibition of bcr-abl and hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells","volume":"21","author":"Wu L","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cbi.2024.111248_bib27","doi-asserted-by":"crossref","first-page":"797","DOI":"10.4161\/cbt.12.9.17671","article-title":"C086, a novel analog of curcumin, induces growth inhibition and down-regulation of NF\u03baB in colon cancer cells and xenograft tumors","volume":"12","author":"Chen C","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.cbi.2024.111248_bib28","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1021\/jm301891t","article-title":"Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-abelson kinase including the T315I mutant","volume":"56","author":"Hong S","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2024.111248_bib29","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ceb.2009.01.014","article-title":"The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl","volume":"21","author":"Eck Mj","year":"2009","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.cbi.2024.111248_bib30","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual src\/abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo Lj","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2024.111248_bib31","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1016\/j.bmcl.2011.09.127","article-title":"Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors","volume":"21","author":"L\u00fc S","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.cbi.2024.111248_bib32","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ejmech.2011.01.020","article-title":"Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors","volume":"46","author":"Zhang C","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cbi.2024.111248_bib33","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.bmc.2013.02.036","article-title":"Design, synthesis and biological activities of Nilotinib derivates as antitumor agents","volume":"21","author":"Pan X","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.cbi.2024.111248_bib34","doi-asserted-by":"crossref","first-page":"10055","DOI":"10.1016\/j.tet.2006.08.065","article-title":"Efficient microwave-assisted synthesis of highly functionalized pyrimidine derivatives","volume":"62","author":"Hartung","year":"2007","journal-title":"Tetrahedron"},{"key":"10.1016\/j.cbi.2024.111248_bib35","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0959-8049(02)80599-8","article-title":"Imatinib: a selective tyrosine kinase inhibitor","volume":"38","author":"Manley Pw","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cbi.2024.111248_bib36","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-19-1236","article-title":"Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation","volume":"79","author":"Burslem","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2024.111248_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26237129","article-title":"Identification of influenza PAN endonuclease inhibitors via 3D-QSAR modeling and docking-based virtual screening","volume":"26","author":"Zhang C","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.cbi.2024.111248_bib38","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/jm301581y","article-title":"Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region\u2013abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib","volume":"56","author":"Ren X","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2024.111248_bib39","first-page":"100","article-title":"Inhibition of the abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger E","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2024.111248_bib40","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4161\/cbt.28931","article-title":"SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells","volume":"15","author":"Bu Q","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.cbi.2024.111248_bib41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejmech.2017.07.031","article-title":"Heme oxygenase-1: a new druggable target in the management of chronic and acute myeloid leukemia","volume":"142","author":"Salerno L","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cbi.2024.111248_bib42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1747-0285.2009.00911.x","article-title":"AP24163 inhibits the gatekeeper mutant of BCR-ABL and SuppressesIn vitroResistance","volume":"75","author":"Azam M","year":"2010","journal-title":"Chem. Biol. Drug Design"},{"key":"10.1016\/j.cbi.2024.111248_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/1947601910371337","article-title":"A non-ATP-competitive dual inhibitor of JAK2V617F and BCR-ABLT315I kinases: elucidation of a novel therapeutic spectrum based on substrate competitive inhibition","volume":"1","author":"Jatiani Ss","year":"2010","journal-title":"Genes & Cancer"},{"key":"10.1016\/j.cbi.2024.111248_bib44","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1073\/pnas.0408283102","article-title":"A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance","volume":"102","author":"Gumireddy K","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.cbi.2024.111248_bib45","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1124\/jpet.106.116640","article-title":"STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells","volume":"321","author":"Greene","year":"2007","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.cbi.2024.111248_bib46","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1091\/mbc.e02-03-0149","article-title":"Calcium regulation of GM-CSF by calmodulin-dependent kinase II phosphorylation of Ets1","volume":"13","author":"Liu H","year":"2002","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.cbi.2024.111248_bib47","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00277-018-3444-0","article-title":"Radotinib-induced eruptive melanocytic nevi in patient with chronic myeloid leukemia: a case report and literature review","volume":"98","author":"Park E","year":"2018","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cbi.2024.111248_bib48","article-title":"Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death","volume":"7","author":"Heo Sk","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cbi.2024.111248_bib49","first-page":"874","article-title":"Combination of axitinib with dasatinib improves the outcome of a chronic myeloid leukemia patient with BCR-ABL1 T315I mutation","volume":"45","author":"Deng Q","year":"2020","journal-title":"J. Cent. S. Univ."},{"key":"10.1016\/j.cbi.2024.111248_bib50","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12964-016-0129-y","article-title":"Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells","volume":"24","author":"Halbach S","year":"2016","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.cbi.2024.111248_bib51","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1586\/14737140.8.9.1387","article-title":"Abl tyrosine kinase inhibitors for overriding Bcr-Abl\/T315I:from the second to third generation","volume":"8","author":"Tanaka R","year":"2008","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.cbi.2024.111248_bib52","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cbi.2024.111248_bib53","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2024.111248_bib54","first-page":"103","article-title":"Pharmacophore mapping: prediction of BCR\u2013ABL kinase inhibitory activity of \u03b1-benzylthio chalcones","volume":"52","author":"Bajaj R","year":"2014","journal-title":"Bull. Fac. Pharm. Cairo Univ."},{"key":"10.1016\/j.cbi.2024.111248_bib55","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.bmcl.2013.01.113","article-title":"BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives","volume":"23","author":"Cui J","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.cbi.2024.111248_bib56","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bmcl.2009.12.047","article-title":"Pharmacophore modeling and virtual screening for designing potential 5-Lipoxygenase inhibitors","volume":"20","author":"Aparoy P","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.cbi.2024.111248_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106641","article-title":"Novel pharmacological approach for the prevention of multidrug resistance (MDR) in a human leukemia cell line","volume":"109","author":"Gupta Sk","year":"2021","journal-title":"Leuk. Res."},{"key":"10.1016\/j.cbi.2024.111248_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106677","article-title":"Exploring the chemical space of functionalized [1,2,4]triazolo[4,3-a]quinoxaline-based compounds targeting the bromodomain of BRD9","volume":"139","author":"Gazzillo E","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.cbi.2024.111248_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126758","article-title":"Structure-based analysis and biological characterization of imatinib derivatives reveal insights towards the inhibition of wild-type BCR-ABL and its mutants","volume":"29","author":"Yang M","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.cbi.2024.111248_bib60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijpharm.2018.07.046","article-title":"Drug metabolites and their effects on the development of adverse reactions: revisiting Lipinski's Rule of Five","volume":"549","author":"Chagas Cm","year":"2018","journal-title":"Int. J. Pharm."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279724003946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279724003946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T16:53:25Z","timestamp":1729616005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279724003946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":60,"alternative-id":["S0009279724003946"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2024.111248","relation":{},"ISSN":["0009-2797"],"issn-type":[{"type":"print","value":"0009-2797"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure optimization, synthesis and bioactivity evaluation of novel BCR-ABL tyrosine kinase inhibitor targeting T315I mutation","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2024.111248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111248"}}